Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Change in Accured Expenses: 2014-2024

Historic Change in Accured Expenses for Rocket Pharmaceuticals (RCKT) over the last 11 years, with Dec 2024 value amounting to $6.1 million.

  • Rocket Pharmaceuticals' Change in Accured Expenses fell 486.22% to -$12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.6 million, marking a year-over-year decrease of 140.90%. This contributed to the annual value of $6.1 million for FY2024, which is 40.21% down from last year.
  • Latest data reveals that Rocket Pharmaceuticals reported Change in Accured Expenses of $6.1 million as of FY2024, which was down 40.21% from $10.1 million recorded in FY2023.
  • Over the past 5 years, Rocket Pharmaceuticals' Change in Accured Expenses peaked at $11.0 million during FY2020, and registered a low of -$4.8 million during FY2021.
  • Its 3-year average for Change in Accured Expenses is $8.6 million, with a median of $9.7 million in 2022.
  • Per our database at Business Quant, Rocket Pharmaceuticals' Change in Accured Expenses spiked by 504.67% in 2020 and then tumbled by 143.82% in 2021.
  • Rocket Pharmaceuticals' Change in Accured Expenses (Yearly) stood at $11.0 million in 2020, then crashed by 143.82% to -$4.8 million in 2021, then surged by 300.41% to $9.7 million in 2022, then grew by 4.89% to $10.1 million in 2023, then slumped by 40.21% to $6.1 million in 2024.